This database contains 14 studies, archived under the term: "Switzerland"
Click here to filter this large number of results.
Mild to moderate cognitive impairment is a major risk factor for mortality and nursing home admission in the first year after hip fracture
Schaller, F.,
Sidelnikov, E.,
Theiler, R.,
Egli, A.,
Staehelin, H. B.,
Dick, W.,
Dawson-Hughes, B.,
Grob, D.,
Platz, A.,
Can, U.,
Bischoff-Ferrari, H. A.
Background: It is not well established if and to what extent mild to moderate cognitive impairment predicts mortality and risk of nursing home admission after hip fracture.; Objective: To investigate prospectively whether and to what extent mild to moderate cognitive impairment, contributes to mortality and admission to nursing home in the first year after acute […]
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
Ostrowitzki, Susanne,
Deptula, Dennis,
Thurfjell, Lennart,
Barkhof, Frederik,
Bohrmann, Bernd,
Brooks, David J.,
Klunk, William E.,
Ashford, Elizabeth,
Yoo, Kisook,
Xu, Zhi-Xin,
Loetscher, Hansruedi,
Santarelli, Luca
Background: Gantenerumab is a fully human anti-Aβ monoclonal antibody in clinical development for the treatment of Alzheimer disease (AD).; Objectives: To investigate whether treatment with gantenerumab leads to a measurable reduction in the level of Aβ amyloid in the brain and to elucidate the mechanism of amyloid reduction.; Design: A multicenter, randomized, double-blind, placebo-controlled, ascending-dose […]
Safety and efficacy of galantamine (Reminyl) in severe Alzheimer’s disease (the SERAD study): a randomised, placebo-controlled, double-blind trial
Burns, Alistair,
Bernabei, Roberto,
Bullock, Roger,
Cruz Jentoft, Alfonso J.,
Frölich, Lutz,
Hock, Christoph,
Raivio, Minna,
Triau, Eric,
Vandewoude, Maurits,
Wimo, Anders,
Came, Elizabeth,
Van Baelen, Bart,
Hammond, Gerry L.,
van Oene, Joop C.,
Schwalen, Susanne
Background: The efficacy of galantamine has been shown in patients with mild, moderate, and advanced moderate Alzheimer’s disease (AD). Here we report its efficacy in patients with severe AD.; Methods: Between December, 2003, and March, 2007, patients aged 84 (SD 6) years with severe AD (mini-mental state examination [MMSE] score 5-12 points), in a nursing […]
Longitudinal assessment of psychotherapeutic day hospital treatment for neuropsychiatric symptoms in dementia
Weber, Kerstin,
Meiler-Mititelu, Corina,
Herrmann, François Robert,
Delaloye, Christophe,
Giannakopoulos, Panteleimon,
Canuto, Alessandra
Objective: Behavioral and psychological symptoms (BPSD) of dementia are associated with more rapid cognitive deterioration as well as increased caregiver stress. The effectiveness of psychiatric day hospital care for this condition remains disputed. We report here the assessment of a psychotherapeutic day hospital program in a series of elderly people with dementia and concomitant BPSD.; […]
Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years
Stoeck, K.,
Sanchez-Juan, P.,
Gawinecka, J.,
Green, A.,
Ladogana, A.,
Pocchiari, M.,
Sanchez-Valle, R.,
Mitrova, E.,
Sklaviadis, T.,
Kulczycki, J.,
Slivarichova, D.,
Saiz, A.,
Calero, M.,
Knight, R.,
Aguzzi, A.,
Laplanche, J.-L.,
Peoc'h, K.,
Schelzke, G.,
Karch, A.,
van Duijn, C. M.,
Zerr, I.
To date, cerebrospinal fluid analysis, particularly protein 14-3-3 testing, presents an important approach in the identification of Creutzfeldt-Jakob disease cases. However, one special point of criticism of 14-3-3 testing is the specificity in the differential diagnosis of rapid dementia. The constant observation of increased cerebrospinal fluid referrals in the national surveillance centres over the last […]
Cognitive dysfunction in HIV patients despite long-standing suppression of viremia
Simioni, Samanta,
Cavassini, Matthias,
Annoni, Jean-Marie,
Rimbault Abraham, Aline,
Bourquin, Isabelle,
Schiffer, Véronique,
Calmy, Alexandra,
Chave, Jean-Philippe,
Giacobini, Ezio,
Hirschel, Bernard,
Du Pasquier, Renaud A.
Objective: To determine the prevalence of cognitive complaints and HIV-associated neurocognitive disorders (HANDs) in a cohort of aviremic HIV-positive patients. To evaluate the relevance of the HIV dementia scale to detect HANDs.; Design: Assessment of HANDs with neuropsychological tests.; Methods: Two hundred HIV-infected patients with undetectable HIV-1 RNA concentrations in the plasma, no history of […]
Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study
Simioni, S.,
Cavassini, M.,
Annoni, J.-M.,
Metral, M.,
Iglesias, K.,
Rimbault Abraham, A.,
Jilek, S.,
Calmy, A.,
Muller, H.,
Fayet-Mello, A.,
Giacobini, E.,
Hirschel, B.,
Du Pasquier, R. A.
Objective: To assess the efficacy and safety of rivastigmine for the treatment of HIV-associated neurocognitive disorders (HAND) in a cohort of long-lasting aviremic HIV+ patients.; Methods: Seventeen aviremic HIV+ patients with HAND were enrolled in a randomized, double-blind, placebo-controlled, crossover study to receive either oral rivastigmine (up to 12 mg/day for 20 weeks) followed by […]